Scroll Back to Top

Labcorp Plasma Detect ID MRD, Baseline

CPT To be determined. Updates will be made when available.

Test Details

Use

Labcorp Plasma Detect ID MRD uses tumor-informed, bespoke assays to detect circulating tumor DNA (ctDNA) in plasma in patients diagnosed with a solid tumor malignancy that are being monitored for recurrence or progression, potentially enabling proactive and timely intervention.

Special Instructions

This test currently is not approved for use in New York state.

Methodology

NGS

Specimen Requirements

Information on collection, storage, and volume

Specimen

FFPE Tumor tissue, whole blood collected in EDTA blood tubes and cfDNA from whole blood collected in Streck BCT tubes

Volume

FFPE block or at least 10 unstained FFPE slides, positively charged cut at 5 µm thickness; 3 mL whole blood in a lavender EDTA tube; two full Streck cell-free DNA block collection tubes (10 mL each)

Minimum Volume

FFPE block or at least 10 unstained FFPE slides, positively charged cut at 5 µm thickness; 1 mL whole blood in a lavender EDTA tube; two full Streck cell-free DNA blood collection tubes (10 mL each)

Container

Lavender-top EDTA tube and Streck cell-free DNA blood collection tube (10 mL) and FFPE

Storage Instructions

Whole blood samples collected in Streck cell-free DNA blood collection tube should be stored at ambient temperature (6°C to 37°C/43°F to 98°F).

Do not freeze collected blood specimens. Specimens must be labeled with collection date and received within six days of collection date. FFPE tissue should be stored at ambient temperatures.

Causes for Rejection

Outside stability window; frozen or refrigerated Streck tube sample

Collection

Collect venous whole blood directly into two Streck BCT tubes and lavender-top EDTA tubes; rotate and invert tubes after filled at time of collection.